桂林三金(002275) - 桂林三金调研活动信息(3)

Group 1: Company Performance - The company's Xigua Frost series suffered significant losses during the pandemic, while the Sanjin Pian series maintained stable sales, becoming the main driver of the company's performance [1] - In 2022, the company experienced a recovery in Xigua Frost sales after the lifting of pandemic controls, with inventory replenishment completed by February 2023 [1] Group 2: Product Composition and Market Strategy - The company has a product composition of approximately 70% OTC (over-the-counter) drugs and 30% prescription drugs, with Sanjin Pian having a slightly higher hospital usage ratio compared to Xigua Frost [1] - The company views centralized procurement of traditional Chinese medicine as an opportunity rather than a challenge, especially for its unique products like Sanjin Pian, which are included in essential drug lists and have limited price reduction potential [1] Group 3: Research and Development - Baoshuan Bio is currently facing losses in R&D, but plans to continue investment in R&D and explore other business models, including financing and partnerships, without losing control [2] - The company expects to obtain 1-2 new clinical approvals in the current year, as part of its strategy to integrate resources and prepare for potential IPO [2]